March 12, 2018 / 12:20 PM / 6 months ago

BRIEF-Anthera Pharmaceuticals Reports Top Line Data From Result Phase 3 Clinical Study Of Sollpura

March 12 (Reuters) - Anthera Pharmaceuticals Inc:

* ANTHERA PHARMACEUTICALS REPORTS TOP LINE DATA FROM THE RESULT PHASE 3 CLINICAL STUDY OF SOLLPURA

* ANTHERA PHARMACEUTICALS INC - ‍SOLLPURA DID ACHIEVE SECONDARY ENDPOINT OF COEFFICIENT OF NITROGEN ABSORPTION​

* ANTHERA PHARMACEUTICALS INC - SOLLPURA DID NOT ACHIEVE PRIMARY ENDPOINT OF COEFFICIENT OF FAT ABSORPTION

* ANTHERA PHARMACEUTICALS INC - FURTHER DEVELOPMENT OF SOLLPURA TO BE DISCONTINUED

* ANTHERA PHARMACEUTICALS INC - ‍ANTHERA TO EVALUATE ALL STRATEGIC ALTERNATIVES​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below